Yakult Reduces Oncology Portfolio As It Looks Towards Microbiome
Multiple Products Transferred
The Japanese firm has decided to shrink its oncology portfolio by transferring its rights to oxaliplatin in Japan, along with a portfolio of generics, to Takata. Though Yakult will maintain an interest in the area through irinotecan and several other anticancers, its has said future R&D investment will shift more towards the microbiome.
You may also be interested in...
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.
Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.